List of Contributors

Agnesini, C., 4–16, 250–261
Albano, E., 444–446
Alfieri, R., 442–443
Algeri, S., 376–383
Amaducci, L., 349–356
Ames, B. N., 85–96
Amstad, P., 158–166
Antonelli, A., 418–420
Astaldi Ricotti, G. C. B., 508–509

Bacci, B., 463–465
Baez, I., 487–489
Ballinger, D. G., 125–138
Bannai, S., 497–498
Barbieri, D., 250–261
Baserga, R., 154-157
Bastianon, V., 423–425
Baynes, J. W., 421–422, 436–437
Bayreuther, K., 167–179
Bellomo, G., 97–109, 250–261
Benedetti, N., 483–486
Bergamini, E., 43–47
Bernardi, M., 494–496
Bernelli-Zazzera, A., 120–124
Bertazzoni, U., 215–217
Bertolini, A., 494–496
Bettuzzi, S., 471–474
Biasi, G., 481–482
Billi, D., 418–420
Borghetti, A. F., 442–443
Borzì, R. M., 508–509
Brianti, V., 505–507
Brioli, G., 499–500

Cairo, G., 120–124
Calvani, M., 483–486
Campanini, C., 442–443
Campisi, J., 195–201
Cantoni, O., 71–73, 456–457
Cappellacci, S., 499–500
Capri, M., 250–261
Carcereri de Prati, A., 432–435
Cardona, F., 418–420
Carini, R., 444–446
Carney, J. M., 110–119
Carta, A., 483–486
Caruso, G., 483–486
Cattabeni, F., 456–457
Cerami, A., 63–70
Cerutti, P., 158–166
Chau, R. M. W., 466–470
Chessa, L., 423–425
Chiricolo, M., 429–431
Ciavarella, A., 429–431
Cinader, B., 294–304
Clark, B. F. C., 48–52
Coeytaux, S., 479–480
Colombo, S., 440–441
Constantin, D., 460–462
Corti, A., 471–474
Cosi, C., 432–435
Cossarizza, A., 4–16, 250–261, 429–431, 490–493, 499–500, 505–507
Coviello, D., 477–478
Crepaldi, G., xi
Cristofalo, E. A., 250–261
Cristofalo, V. J., 187–194

Dal, V., 508–509
Dal Toso, R., 463–465
de Kloet, E. R., 357–371
de Leeuw, W. J. F., 26–35
Del Porto, G., 423–425
Derventzi, A., 48–62
Detorie, N. J., 436–437
Dianzani, M. U., 444–446
Díaz, J., 487–489
Donelli, G., 218–233
Douglas, G. R., 26–35
Dunn, J. A., 421–422
Dyer, D. G., 421–422, 436–437

Elli, R., 418–420
Emilia, G., 4–16
Eylar, E. H., 487–489

Fabris, N., 335–348
Facchinetti, A., 481–482
Facchini, A., 508–509
Fagiolo, U., 490–493
Fagnoni, F., 505–507
Falcini, M., 349–356
Ferrari, S., 180–186, 202–214
Finn, J. P., III, 396–402
Floyd, R. A., 110–119
Focher, F., 440–441
Fornace, A. J., Jr., 139–153
Franceschi, C., 4–16, 250–261, 412–417, 429–431, 460–462, 471–474, 490–493, 499–500, 505–507
Francz, P. I., 167–179
Friedman, E., 426–428

Gauldie, J., 479–480
Gee, P., 17–25
Genedani, S., 494–496
Giacomoni, P. U., 1–3, 447–449, 456–457

List of Contributors

Agnesini, C., 4–16, 250–261
Albano, E., 444–446
Alfieri, R., 442–443
Algeri, S., 376–383
Amaducci, L., 349–356
Ames, B. N., 85–96
Amstad, P., 158–166
Antonelli, A., 418–420
Astaldi Ricotti, G. C. B., 508–509

Bacci, B., 463–465
Baez, I., 487–489
Ballinger, D. G., 125–138
Bannai, S., 497–498
Barbieri, D., 250–261
Baserga, R., 154-157
Bastianon, V., 423–425
Baynes, J. W., 421–422, 436–437
Bayreuther, K., 167–179
Bellomo, G., 97–109, 250–261
Benedetti, N., 483–486
Bergamini, E., 43–47
Bernardi, M., 494–496
Bernelli-Zazzera, A., 120–124
Bertazzoni, U., 215–217
Bertolini, A., 494–496
Bettuzzi, S., 471–474
Biasi, G., 481–482
Billi, D., 418–420
Borghetti, A. F., 442–443
Borzì, R. M., 508–509
Brianti, V., 505–507
Brioli, G., 499–500

Cairo, G., 120–124
Calvani, M., 483–486
Campanini, C., 442–443
Campisi, J., 195–201
Cantoni, O., 71–73, 456–457
Cappellacci, S., 499–500
Capri, M., 250–261
Carcereri de Prati, A., 432–435
Cardona, F., 418–420
Carini, R., 444–446
Carney, J. M., 110–119
Carta, A., 483–486
Caruso, G., 483–486
Cattabeni, F., 456–457
Cerami, A., 63–70
Cerutti, P., 158–166
Chau, R. M. W., 466–470
Chessa, L., 423–425
Chiricolo, M., 429–431
Ciavarella, A., 429–431
Cinader, B., 294–304
Clark, B. F. C., 48–52
Coeytaux, S., 479–480
Colombo, S., 440–441
Constantin, D., 460–462
Corti, A., 471–474
Cosi, C., 432–435
Cossarizza, A., 4–16, 250–261, 429–431, 490–493, 499–500, 505–507
Coviello, D., 477–478
Crepaldi, G., xi
Cristofalo, E. A., 250–261
Cristofalo, V. J., 187–194

Dal, V., 508–509
Dal Toso, R., 463–465
de Kloet, E. R., 357–371
de Leeuw, W. J. F., 26–35
Del Porto, G., 423–425
Derventzi, A., 48–62
Detorie, N. J., 436–437
Dianzani, M. U., 444–446
Díaz, J., 487–489
Donelli, G., 218–233
Douglas, G. R., 26–35
Dunn, J. A., 421–422
Dyer, D. G., 421–422, 436–437

Elli, R., 418–420
Emilia, G., 4–16
Eylar, E. H., 487–489

Fabris, N., 335–348
Facchinetti, A., 481–482
Facchini, A., 508–509
Fagiolo, U., 490–493
Fagnoni, F., 505–507
Falcini, M., 349–356
Ferrari, S., 180–186, 202–214
Finn, J. P., III, 396–402
Floyd, R. A., 110–119
Focher, F., 440–441
Fornace, A. J., Jr., 139–153
Franceschi, C., 4–16, 250–261, 412–417, 429–431, 460–462, 471–474, 490–493, 499–500, 505–507
Francz, P. I., 167–179
Friedman, E., 426–428

Gauldie, J., 479–480
Gee, P., 17–25
Genedani, S., 494–496
Giacomoni, P. U., 1–3, 447–449, 456–457

Gogol, J., 167–179
Gossen, J. A., 26–35
Grande, A., 180–186, 202–214
Grassilli, E., 250–261, 471–474
Guidarelli, A., 456–457
Guigoz, Y., 479–480

Hanawalt, P. C., 17–25
Healy, A. M., 319–330
Heydari, A. R., 384–395
Ho, L., 17–25
Hoffman-Liebermann, B., 139–153
Hogan, N. C., 125–138
Hollander, M. C., 139–153
Hsu, R. K., 17–25
Huang, W. Q., 466–470
Huggins, T. G., 436–437
Hughes, T. K., Jr., 396–402

Iannuccelli, M., 483–486
Ingletti, M. C., 471–474
Ishii, T., 497–498
Itzhaki, R. F., 438–439

Jackman, J., 139–153
Jenkinson, E. J., 305–310
Joenje, H., 453–455
Juillerat, M., 479–480

Kaczmarek, L., 458–459
Kaminska, B., 458–459
Kane, C. J. M., 17–25
Karelus, K., 501–504
Khokhlov, A. N. 475–476
Kimura, T., 396–402
Kirkwood, T. B. L., 412–417
Knook, D. L., 372–375
Kontermann, K., 167–179

Lambert-Gardini, S., 499–500
Lee, A. T., 63–70
Leung, M. K., 396–402
Leuzzi, V., 418–420
Liebermann, D. A., 139–153
Lioi, M. R., 4–16
Lippi, A., 349–356
Lloyd, D. C., 438–439
Lockshin, R. A., 234–249
Lulli, P., 499–500
Lyons, T. J., 421–422

Maga, G., 440–441
Mallozzi, L., 396–402
Malorni, W., 218–233
Manfredi, B., 311–318
Manfredini, R., 180–186, 202–214
Marcato, A., 505–507
Marcucci, L., 418–420
Mariethoz, E., 319–330
Mariño, R., 487–489
Markesbery, W. R., 110–119
Masoro, E. J., 403–411
Mazzarello, P., 440–441
McCabe, M. J., Jr., 269–278
McCance, D. R., 421–422
Meliconi, R., 508–509
Menegazzi, M., 432–435
Mirabelli, F., 97–109
Miura, K., 497–498
Moldèus, P., 460–462
Molina, C., 487–489
Mondello, C., 440–441
Montealegre, F., 487–489
Montecucco, C. M., 508–509
Monti, D., 250–261
Monti, D., 4–16, 250–261, 429–431, 460–462, 471–474, 490–493, 499–500, 505–507
Morellini, M., 499–500
Muiras, M. L., 447–449

Nardo, T., 423–425
Natarajan, A. T., 36–42
Neary, D., 438–439
Negri, C., 508–509
Negroni, M., 508–509
Nelson, J. F., 501–504
Nicotera, P., 269–278
Nunzi, M. G., 463–465

Orr, W. C., 74–84
Orrenius, S., 269–278
Orru, D., 499–500
Ortolani, C., 490–493
Ottaviani, E., 331–334
Owen, J. J. T., 305–310

Paganelli, R., 490–493
Pagani, F., 477–478
Panerai, A. E., 311–318
Panozzo, M., 481–482
Pardue, M. L., 125–138
Parola, M., 444–446
Passeri, G., 505–507
Pennesi, G., 499–500
Pertile, P., 481–482
Peskin, A., 158–166
Peterson, C., 279–293
Petrelli, L., 463–465
Petrinelli, P., 418–420
Petronini, P. G., 442–443
Pignolo, R. J., 187–194

Pikó, L., 450–452
Pisano, M. R., 426–428
Pizurki, L., 319–330
Polla, B. S., 319–330
Pruijn, F. B., 453–455
Pryor, S., 396–402

Rattan, S. I. S., 48–62
Ren, F., 466–470
Richardson, A., 384–395
Richter, C., 262–268
Rivera-Quñones, C., 487–489
Ronchetti, I., 250–261
Rotenberg, M. O., 187–194
Ruffieux, C., 479–480

Sacerdote, P., 311–318
Sagara, J.-I., 497–498
Salvioli, S., 4–16, 250–261
Sansoni, P., 4–16, 499–500, 505–507
Santacaterina, S., 490–493
Sato, H., 497–498
Scarfí, M. R., 4–16
Schiaffonati, L., 120–124
Schlegel, J., 262–268
Schoonen, W. G. E. J., 453–455
Schweizer, M., 262–268
Scovassi, A. I., 215–217, 508–509
Sestili, P., 456–457
Shah, G., 158–166
Shigenaga, M. K., 85–96
Sierra, F., 479–480
Sikora, E., 458–459
Smith, C. D., 110–119
Smith, E. M., 396–402
Snelli, G., 505–507
Sohal, R. S., 74–84
Spadari, S., 440–441
Stadtman, E. R., 110–119
Staton, M. W., 436–437
Stefanini, M., 423–425
Stefano, G. B., 396–402
Stefano, J. M., 396–402
Suzuki, H., 432–435

Tacchini, L., 120–124
Tachon, P., 447–449
Tates, A. D., 36–42
Tatsumo, T., 110–119
Temperani, P., 4–16
Thorpe, S. R., 421–422, 436–437
Tobi, S. E., 438–439
Tomasi, A., 460–462
Torelli, G., 202–214
Torelli, U., 180–186, 202–214
Trabace, S., 499–500
Troiano, L., 4–16, 250–261, 471–474
Tropea, F., 250–261

Van Zeeland, A. A., 36–42
Vannini, P., 429–431
Vergani, C., 477–478
Verri, A., 440–441
Vijg, J., 26–35
Vrieling, H., 36–42

Walla, M. D., 436–437
Wang, H. Y., 426–428

Zagato, L., 477–478
Zakeri, Z. F., 234–249
Zeni, O., 4–16
Zucconi, G. G., 432–435

Subject Index

ACTH, 331–332
  and aging, 357
  HPA axis release of, 358
AD. *See* Alzheimer's disease
Advanced glycosylation endproducts (AGEs). *See also* Amadori products
  in aging, 64
  in diabetes, 54, 65–66
  and glycated myelin, 67
Age-related changes
  in adrenoceptor density, 295
  in autoimmunomodulation, 397–400
  in BE-containing neuron populations, 502
  in brain Ca^{2+} content, 279, 283
  in brain weight/size, 349
  in calcium-binding proteins, 284
  in calcium-channel binding, 280–281
  in calcium-coupled receptors, 283–284
  in Ca^{2+}-mediated processes, 282–283
  in Ca^{2+} transport, 279–281, 283
  in cell population/products, 298
  in cytosolic-free calcium, 281–282, 287
  in fibroblast stem cell systems, 168, 171–173, 175
  genetic programs in, 294–302
  in glucocorticoid regulation, 381
  in G protein function, 426–428
  in hsp expression, 442–443
  in IL synthesis, 297–298, 300–301
  in immune system, 396–397
  in immunosuppression, 295–297, 300–302
  in neuroendocrine system, 341
  in neuronal density, 502
  in neuronal size, 349
  in NK cell efficiency, 336–337, 341
  in NMDA receptors, 284
  in opioid-responsive cell populations, 399–400
  in PKC activity, 284
  in serum BRA levels, 350
  in spectrin proteolysis, 288
  in stationary cell cultures, 475
  in synapsin I mRNA expression, 463–464
  in T-cell function, 336–337, 341
  in thymic endocrine activity, 336–337, 341
  in thymus, 336–341
Age-related deterioration
  calorie-restricted diet and, 376–381
  carnitine treatment and, 380–381
Age-related diseases, 26, 63, 110
  calorie-restricted diet and, 384
Age-related OFR sensitivity, 252
Age-related protein oxidation, 114–116
Aging, 168. *See also* Age-related changes; Antiaging strategies; Life span; Progeroid syndromes
  abnormal proteins and, 44
  ACTH levels during, 357
  and AD, 114–116
  antioxidants and, 74, 76–78, 251
  apoptosis and, 168, 174, 176–177, 246–247
  and autoimmunomodulation, 399–400
  BE in, 311–317
  body fat content and, 385
  brain protein oxidation, 110–116
  brain weight reduction in, 249
  calcium-dependent functions during, 286
  and calmodulin, 284
  Ca^{2+}-dependent function during, 286
  Ca^{2+} role in, 279–288
  cell damage accumulation during, 475
  cell proliferation and, 252–253
  cellular defense mechanisms and, 1–6, 71–73, 414–417
  and cellular proteolysis, 44–45
  and centenarians studies, 5–7
  and CNS function, 376
  complexity of, 416–417
  cytokine production in, 490–492
  degenerative changes in, 357
  as development component, 295
  dietary restriction and, 373–374, 403–409
  DNA damage and, 6–7, 22
  DNA repair and, 1–3, 17–18, 176
  and DNA synthesis, 49–50
  evolutionary perspective, 331–333, 412–414
  genotoxic agents and, 4
  and glutamine synthetase activity, 115
  growth-arrest genes and, 149–151
  Hayflick phenomenon in, 250
  and hippocampus, 357, 365–366
  and HLA antigens, 499–500
  homeostasis and, 357
  and HPA axis, 364
  and hsps, 319–328, 442–443
  hypercorticism and, 357
  immune biomarkers of, 336–337
  and immunoneuroendocrine system, 331–333
  and *lac*Z mutation frequency, 33
  and lens protein oxidation products, 436–437
  in leukemic blast cells, 210–211
  Maillard reaction products in, 421–422
  metabolic rate and, 74–76, 85–86
  MHC in, 499
  and mitochondrial DNA, 450–452

and modified nucleotide accumulation, 18
and MRs/GRs, 366–368
and mutation frequency, 26–27
NADH/NAD^+ ratio, 76
neuroendocrine biomarkers of, 337–338
neuroimmunology and, 397
OFR and, 252–255, 257–259
and opioid peptides, 398–400
and oxidative damage biomarkers, 436–437
oxidative stress and, 76–82, 252–253
and PBMC BE concentration, 311–317
polymorphism of, 295–302
and POMC gene expression, 501–503
posttranslational protein modification and, 43–45, 48–57
pre-mRNA processing during, 477
programmed cell death and, 235, 246–247, 415–416
prooxidants and, 74, 78–82
protein oxidation and, 110–116
and protein synthesis, 48, 174, 176
ROS and, 75–76, 79–82
SGP-2 in, 473
and spatial memory deficits, 463–464
stationary cell culture studies of, 475
stochastic cell death and, 415–416
stress and, 368–369
T-cell mitogenic response during, 487–488
terminal differentiation and, 168–177
theories of, 85, 335–336, 342–345
and transformation, 171–172, 174–177
Alzheimer's disease
calcium-dependent functions in, 286
Alzheimer's disease (AD), 11, 19, 26. *See also* Dementia; Multiinfarct dementia
age-related lesions in, 349
age-relatedness of, 115
age-related protein oxidation in, 114–116
altered protein phosphorylation in, 287
amyloid plaques in, 115–116
autoantibody populations in, 350–352
BE in, 311–317
brain areas affected in, 115–116
and brain-oxidized protein levels, 110
and BRA levels, 350
Ca^{2+}-dependent function in, 286
calcium processes alterations in, 287
carnitine action in, 483
cell-mediated damage in, 352–353
complement pathway in, 350–352
DNA repair in, 438
fibroblast calcium cor'ent in, 286–287
free radical oxidation hypothesis of, 115–116
genetic factors in, 349
head trauma and, 350
immune system disorders and, 350, 353
immunological mechanisms in, 349–353
MHC in, 352
microglia and, 352–353
neuropathologic features of, 115–116
and PBMC BE concentration, 311–317
phosphorylation and, 98
PKC levels in, 288
SGP-2 in, 472
spectrin proteolysis increase in, 288
Amadori products, 63–64, 67. *See also* Advanced glycosylation endproducts
Amino acids
and cytotoxic response, 71–73
free radical sensitivity of, 111
Amyloidosis frequency, in DS, 11
Antiaging mechanisms
energy intake, 384, 405–407
metabolic rate, 406
Antiaging strategies, 372–375
and biological organization levels, 372–373
and brain deterioration, 376–381
calorie-restricted diet in, 384–392
and glucocorticoid homeostasis, 381
at organismic level, 373
technological approach, 374–375
Antigen-presenting cells (APC)
antigen entry processes, 325
in apoptosis induction, 307
hsps and, 325–327
and negative selection, 308–309
and thymic epithelial cells, 308
Antioxidant agents
as antimutagens, 87–88
and cancers, 86
carnitines, 252, 254-255, 257
deficiencies of, 88, 90
dietary, 87–90
enzymes as, 158–161, 164
fruits/vegetables as, 90
and life span, 414, 417
nicotinamide, 254–255, 257
Antioxidant defenses
age-related declines in, 76–78
and aging process, 74
in cellular defense mechanisms network, 5
enzymes in, 158–161, 164
and MLSP, 78–82
and oxidant carcinogenesis, 158–161
and oxidative stress levels, 76–78
Antioxidant enzyme transfectants, 159–161
Antioxidant systems
in cellular defense mechanisms network, 5
Antisense strategy, 208–210
AP1 complex, 162–164
age-related formation of, 458
Con A-stimulated formation of, 458–459
protooncogene products in, 123–124

Apoptosis. *See also* Cell death; Necrosis; Programmed cell death
aging and, 168, 174, 176–177, 246–247
APCs and, 307
bcl-2 expression and, 228
blebbing in, 227, 229–230
Ca^{2+} concentration in, 270, 273–274, 307
Ca^{2+}-dependent endonuclease in, 471
cAMP-elevating agents and, 272
cell senescence and, 250–251
in cellular defense mechanisms, 5
characteristics of, 218
cytokines in, 276
cytosolic Ca^{2+} concentration and, 307
DNA-damaging agents and, 146
and DNA fragmentation, 253, 269
endonuclease activity in, 246, 269, 271, 276
glucocorticoid induction of, 306
in HIV infection, 228
interleukins and, 184, 272
kinase inhibitors and, 271
kinases in, 273
and malignancy, 227
of mature T lymphocytes, 481–482
myeloid differentiation and, 146
necrosis distinguished from, 231
nuclear morphology in, 240, 242
PADPRP activation in, 215
phorbol esters and, 271, 307
PKC role in, 273, 276, 307
programmed death distinguished from, 234–235
protein inhibitors and, 306
and protein synthesis, 244
protooncogenes and, 184, 471
in SEB-activated cells, 481-482
SGP-2 expression in, 471–472
spermine and, 274
and T-cell maturation, 269
and T-cell selection, 305–309, 481
TCR induction of, 306
and terminal differentiation, 168, 174, 176–177, 184–185
and thymic changes, 294
in thymocytes, 269–273
transformation prevention by, 5, 471
and tumor growth, 250–251
Arginine
in lymphocyte proliferation, 342
in thymic "rejuvenation," 339, 341
Atherosclerosis, 26, 63
ATP depletion, 97–98
Autoimmune diseases, 508
HLA and, 499
hsps in, 323–324
PADPRP antibodies in, 508–509
Autoimmunomodulation, 396–400

BE. *See* β-Endorphin
Biomarkers of aging
criteria for, 335
immune, 336–337
in lens protein, 436–437
neuroendocrine, 337–338
Bleb formation, 218, 222, 225
in apoptosis, 227, 229–230
Ca^{2+}-dependent proteases in, 101
Ca^{2+} in, 99–100
Clostridium difficile toxins and, 220, 223
cytoskeletal toxins and, 97
in necrosis, 229–230
oxidative stress and, 97–98
potocytotic, 227, 229–231
TNF-α and, 220–222, 227
zeiotic, 227, 229–230
Blood-brain barrier (BBB) function
AD and, 350–352
immunoglobulin synthesis in, 351
Bloom's syndrome, 6
Brain-oxidized protein
and AD, 110, 114–116
and age-related CNS disease, 110
and aging, 110
free radicals and, 110–116
glutamine synthetase, 112–113
protein carbonyl, 111–112

Ca^{2+}
in actin-binding, 100
age-related binding of, 279–281
age-related brain content of, 279
age-related transport of, 279
in bleb formation, 99–101
and cytoskeletal alterations, 98
in cytoskeletal organization/function, 100
as intracellular messenger, 279
in liver injury pathogenesis, 444, 446
mitochondrial release of, 262–266
prooxidant-induced release of, 262–266
release pathways, 264–266
Ca^{2+} concentration
age-related changes in, 279
and apoptosis, 270, 273–274, 307
in DNA fragmentation, 273–274
and endonuclease activation, 271
Ca^{2+}-dependent proteases
activation of, 101
in bleb formation, 101
oxidative modification of, 100
Calcium channel changes, during aging, 280–281, 283
Calcium-mediated processes, 282–283
Calmodulin, aging and, 284
Calorie-restricted diet. *See also* Dietary restriction

and ACh release, 379–380
and age-associated diseases, 403–404
and age-related deterioration, 376–380
antiaging action of, 384–392, 403–409
and antioxidant enzyme expression, 387–388
and cancer reduction, 91
and cognitive behavior, 378–379
and disease, 384
and energy metabolism, 384, 405–406
and gene expression, 386
and GSH levels, 378
and hormone levels, 378
and hsp expression, 389–390
and life span, 91, 373–374
mechanisms of, 385–386
and metabolic rate, 406
and mitogenesis rates, 91–92
and MLSP extension, 92
in nonmammalian species, 404–405
pathological observations in, 377–378
and protein synthesis, 386–390
Calpain. *See* Ca^{2+}-dependent proteases
Cancer. *See* Carcinogenesis
Carcinogenesis, 185, 322
antioxidant defenses in, 158–161
calorie restrictions and, 91–92
chronic mitogenesis in, 88–90, 92
endogenous oxidants and, 86
epigenetic factors in, 90
genotoxic agents and, 90
growth control mechanisms and, 149–150
oxidants in, 158–164
promoters and, 89
Carnitines
and age-related deterioration, 380–381
in Alzheimer's disease, 483
as antioxidant agents, 253–255, 257–258
in dementia, 483–486
Catalase (CAT)
in antioxidant defenses, 158–189, 164
dietary restriction and, 387–389, 391
and DNA breakage, 161
and life span, 78
transfectant cells with, 159–161
Cataracts
in DS, 11
glycated proteins and, 63, 65
Ca^{2+} transport
in aged brain, 281
age-related changes in, 279
Cell cycle
cytokines in, 181–182
genes in, 187, 189
genotoxic agents and, 150–151
growth arrest in, 180–181
IGF-1 receptor and, 154–156
leukemic blast cell characteristics in, 202–205
molecular monitoring of, 203–204
oncogenes in, 181
ribosomal proteins in, 205–206
Cell death. *See also* Apoptosis; Necrosis; Programmed cell death
morphological aspects of, 218–231
OFR-DNA damage in, 253–255, 258
Cell injury
death process stages in, 230–231
features of, 228
in HIV infection, 227
mechanisms underlying, 227–231
in neoplasia, 227
subcellular modifications in, 229
Cell metabolism. *See also* Metabolic rate
in heat shock, 126–128
Hsr-omega gene in, 134–137
Cell morphology modification
blebbing, 218, 222–223, 225, 227, 229–230
by chemical agents, 220–227
by TNF-α, 220–222
Cell proliferation
and aging, 252–253
antisense strategy and, 208–210
and differential capacity, 208–211
Hayflick phenomenon, 250
in leukemic blast cells, 202–204, 206, 210–211
and life span, 250
in OFR-stressed cells, 252–253
onocogenes in, 181
protooncogenes and, 458, 471
signal reception in, 181–182
Cell stress
elevated temperature and, 321–322, 325
HSF modification of, 128
and hsp synthesis, 127–128
metabolic changes in, 126–128
oxidative injury, 319–328
responses. *See* Cellular defense mechanisms; Heat shock response; Stress responses
rRNA processing in, 128
Cellular defense mechanisms network, 4
aging and, 1–3
antisense strategy and, 208–210
apoptosis in, 5
efficiency of, 5–6
homeostasis in, 5
hsps in, 319–328
and life span, 414–417
against oxidative stress, 71–73
PADPRP in, 5, 215–216
thermoprotection, 125–126
Cellular growth arrest, 187

Cellular senescence. *See* Senescence
Centenarians
  in aging studies, 5–6
  genomic instability in, 6–7, 13–14
  NK cell activity in, 505–506
  T-lymphocyte proliferation in, 505–506
Chaperones, 126
  conformation-dependent function of, 320
  function of, 319–320
  hsps as, 319, 327
Chemotaxis, opioid peptides and, 398
CHO cells mutants, 72–73
Chromatid breaks. *See also* DNA damage; DNA fragmentation
  bleomycin-induced, 6–8
  MN and, 7, 9
  SCE, 6–7
Chromatin conformation
  and apoptosis, 269, 271, 276
  and DNA fragmentation, 274–275
  and endonuclease activity, 274–276
Clostridium difficile toxins, 220, 223
Cockayne syndrome (CS), 22
  DNA damage and, 418–420
Compartmentalization
  and age-related development, 294
  of aging controls, 297
  analysis of, 298–300
  mapping of, 295
  and subcompartment interaction, 294–302
Concanavalin A (Con A)
  and AP1 complex formation, 458–459
  and endonuclease activation, 271
  T-cell mitogenesis activation by, 487–488
Corticosteroids
  chronic hypersecretion effects of, 357
  and hippocampus damage, 359
  HPA axis release of, 358
  and neuronal loss, 359–360
  in receptor balance hypothesis, 363–364
  receptor diversity, 360
Cryptogenic fibrosing alveolitis (CFA), 508
Cu, Zn-SOD. *See* Superoxide dismutase
Cyclobutane pyrimidine dimers (CPD)
  as DNA damage lesion, 19–22
  repair of, 18–19, 22–23
Cystine transport activity, 497–498
Cytokines, 331. *See also* Interferon; Interleukins
  age-related production of, 490–492
  in apoptosis, 276
  in cell cycle, 181–182
  in DNA fragmentation prevention, 274
  in immune response modulation, 490
  in neuroendocrine-immune interactions, 338–339
  and NK cell function, 337, 344
Cytoskeletal alterations
  by ATP depletion, 97–98
  by Ca^{2+}-dependent mechanisms, 99–101
  Ca^{2+} homeostasis in, 98
  calmodulin mediation of, 322
  by oxidation agents, 101–106, 322
  by phosphorylation, 98–99
Cytotoxic response, 71–73

DDI. *See* DNA-damage-inducible (DDI) genes
Degenerative diseases, 90–91
Dementia. *See also* Alzheimer's disease; Multiinfarct dementia
  and age-related spatial memory, 463–464
  BRA levels in, 350
  carnitine action in, 483–486
  complement pathway in, 350–351
  genetic factors in, 349
  microglia and, 352
  Parkinson's, 351
  synaptic loss in, 349
Diabetes, 294
  collagen cross-linking in, 65–66
  in DS, 11
  glycation and, 65–67
  Maillard reaction products in, 421–422
  reduced BBB function in, 351
  in Werner's syndrome, 430
Dietary imbalance, and heart disease, 90–91
Dietary restriction. *See also* Calorie-restricted diet
  and aging, 373–374
  antiaging action of, 403–409
  energy intake factor in, 384, 405–407
  and glucocorticoid levels, 407–409
  and hsp expression, 387–389, 391
  human applications, 374
  and metabolic rate, 406
  and MLSP, 403, 409
  and MRDT, 403, 409
  and serum T-kininogen levels, 479
Differentiation. *See also* Terminal differentiation
  antisense strategy and, 208–210
  and apoptosis, 146
  arrest of, 202–204, 206–210
  blockage of, 181
  cell growth and, 180–181
  DNA rearrangement in, 182
  mechanisms controlling, 209–210
  oncogenes in, 181
  and proliferation potential, 208, 211
  proliferative pathway genes and, 181
  protooncogenes and, 458
  retinoids in, 182
  signal reception in, 181–182

DNA
glycation of, 63, 67–69
nicking, 447–449
in programmed cell death, 240–242
selective modification of, 182
in stressed cells, 128
DNA breakage. *See* DNA damage
DNA damage, 5, 22–23, 36. *See also* Chromatid breaks; DNA fragmentation
accumulation of, 1–3, 110
agents in, 6
and aging, 6–7, 14, 85
antioxidant deficiencies and, 88, 90
in apoptosis, 146, 253, 269
and cell cycle, 142
and cell death, 253–255
and Cockayne syndrome, 418–420
consequences of, 150
by endogenous mutagens, 85–86, 90
folate deficiency and, 90–91
genes induced in, 139–142
L-histidine and, 456–457
metabolic rate and, 92
mitogenesis and, 88
MMC-induced, 7–8, 11–13
and necrosis, 218
OFR-induced, 106, 253–255, 258
by oxidants, 85–90, 161
peroxide-induced, 447–449, 456
in progeroid syndromes, 6
SCE, 6–7, 10
Zn^{2+} blockage of, 216
DNA-damage-inducible (DDI) genes
agents inducing, 141–142
and growth responses, 139–140, 142–145, 149–151
in mammalian cells, 140–142
PKC and, 142
regulation of, 148–149
DNA fragmentation. *See also* Chromatid breaks; DNA damage
agents preventing, 272–274
age-related increase in, 6
Ca^{2+} concentration in, 271, 273–274
chromatin conformation and, 274–275
and genomic instability, 6
kinase inhibitors and, 271–273
metal ion regulation of, 271
micronuclei and, 7, 9
in SEB-activated cells, 482
DNA repair, 1–2, 5–6, 13–14, 36, 252
in AD lymphocytes, 438
aging and, 3, 17–18, 22–23
in brain, 432–435
calorie-restricted diet and, 91
carnitine and, 255, 257–258
cell senescence and, 176
in cellular defense mechanisms network, 5
in differentiating myoblasts, 19–20
and dimer removal, 18–20
DNA poly β in, 432–435
genomic heterogeneity of, 17–23
glycosylases in, 85–86
and life span, 3, 17–18, 413–414, 417
measurement of, 21–22
nerve growth factor and, 19
in neuronal cell system, 18–19
PADPRP in, 254–255, 257–258, 432–435
UDS quantification of, 3, 17
in UV-irradiated cells, 18–19
in wound healing genes, 20–21
DNA synthesis. *See also* Unscheduled DNA synthesis
aging and, 49–50
and *gadd* induction, 143
L-histidine inhibition of, 456
in leukemic blast cell cycle, 203
with senescence, 187, 189, 191
T antigen-stimulated, 198–200
Down's syndrome (DS). *See also* Neonatal progeroid syndrome; Werner's syndrome
genomic instability in, 11–14
immunological alterations in, 429
leukemia susceptibility in, 11
MMC-induced MN frequency in, 12
and PBMC BE concentration, 311–317
progeroid characteristics in, 11
senescent phenotype in, 11–12, 14
spontaneous MN in, 12
stress-induced cell damage in, 252–253, 255
zinc therapy in, 216
DS. *See* Down's syndrome

EFs. *See* Protein elongation factors
eIFs. *See* Protein initiation factors
Endocytosis, receptor-mediated, 325–326
Endonucleases
in apoptosis, 269, 271, 276
Ca^{2+} in, 271
calcium-dependent, 322
chromatin conformation and, 274–276
kinase regulation of, 273
PADPRP and, 275
β-Endorphin (BE). *See also* Opioid peptides
in AD, 312–317
age-related levels of, 311–317, 399–400
distribution of, 311, 398–399
in DS, 312–317
in immunoneuroendocrine system, 331
in immunoregulatory processes, 399–400
in NK cell activity, 342

in PBMC, 312–317
PHA stimulation and, 312–317
and PMNs, 398
β-Endorphin (BE) concentration
age-related changes in, 311–317
in Alzheimer's disease, 312–317
in Down's syndrome, 312–317
Energy metabolism
dietary restriction and, 405–406
phosphorylation regulation in, 51
met-Enkephalin. *See* Opioid peptides
Erythrophagocytosis
hsp induction by, 327
stress protein synthesis during, 327–328

Fanconi's syndrome, 6
Food restriction. *See* Dietary restriction
Free radicals, 139. *See also* Oxidants
age-dependent formation of, 460–462
amino acids sensitive to, 111
in brain protein oxidation, 110–116
and hsp activation, 122–123
sources of, 111

Gene expression
calorie-restricted diet and, 386–392
in cell death, 227–228
differential, 182–183
and differentiation, 207–208
estrogenic modulation of, 501–503
in leukemic blast cell cycle, 203–204
posttranslational regulation of, 184, 205–206
and proliferation, 207–208
in quiescent cells, 195–201
reorganization of, 183
repression of, 197–201
with senescence, 188–192, 195–201
Genes. *See also* Gene expression; Oncogenes; Protooncogenes
antiapoptotic, 184
cell-cycle-related, 187–188, 202–204
and cell senescence, 250–251
DDI, 139–142
differentially expressed, 187
gadd. *See* Growth-arrest genes
genotoxic stress response, 139–151
in programmed cell death, 243–246
TCR, 305
tumor-suppressor, 196–197, 200–201
Genomic instability, 251
in aging process, 4, 13
in centenarians, 5, 13–14
chromatid breaks and, 6
in DS, 11–13
and micronuclei, 7–8
in neonatal progeroid syndrome, 423–425
SCE and, 6–7
Genotoxic agents, 90, 139–142
body heat, 4
and *hprt* mutations, 38–40
physical, 4
Werner's syndrome cell sensitivity to, 429–430
Genotoxic-stress-response genes, 139–151
Glucocorticoid receptors (GR)
distribution of, 361
in hippocampus damage, 359–360
in homeostatic control, 357
in senescence, 368
in stress response, 361–363
Glucocorticoids
ACTH and, 358
and age-related calcium influx, 284–285
age-related regulation of, 381
and aging, 368
apoptosis induction by, 306
in brain-aging hypothesis, 360, 368–369
dietary restriction and, 407–409
and NMDA receptor activation, 285
and protein synthesis patterns, 244–245
in stress response, 360
wound-healing inhibition by, 21
Glutamine synthetase
in AD, 115
age-related oxidation of, 112–113
glial cell inactivation of, 116
oxidation sensitivity of, 113–114
Glutathione (GSH). *See also* GSH peroxidases
as antioxidant, 101–103
in cell defense network, 497
and cystine transport activity, 497
Glycation
and age-related pathologies, 54, 63
in aging, 54–55, 75
biological consequences of, 65–69
and diabetic complications, 65–67
of DNA, 67–69
of nerve myelin, 66–67
G protein function, 426–428
GR. *See* Glucocorticoid receptors
Growth-arrest genes (*gadd*), 139–142
agents inducing, 143–144
and aging, 149–151
in cell cycle, 180–181
changes critical for, 199–200
and differentiation, 208
IL-6 and, 145
induction of, 143
in leukemic blast cells, 205–206
in malignant cells, 149–150

and mRNA stability, 149
MyD overlap with, 145–146
and myeloid differentiation, 145–146
regulation of, 148–149
transformation and, 149–150
Growth inhibition, 160–161
Growth promotion, 161–162, 164
GSH peroxidases (GPx), 158–160

Hayflick phenomenon, 167, 475
and aging, 250
Heart disease, dietary imbalance and, 90–91
Heat shock
and cell metabolism, 126–128
and cell structure modification, 220
DDI induction in, 140
and hsp synthesis rates, 129–130
and mRNA induction, 128–131, 133
and preferential mRNA translation, 129–133
and ribosome number, 131, 133
Heat shock factor (HSF)
and hsp 70 gene activation, 122
in hsp induction, 128
Heat shock proteins (hsps). *See also* Stress proteins
age-related decrease in, 442–443
age-related expression of, 328
in antigen processing, 325–327
as antigens, 323
in autoimmune diseases, 323–324
in cell death, 237–238, 245
in cellular defense mechanisms, 319–328
chaperone function of, 126, 319–320, 442
cytoskeleton interaction with, 321
erythrophagocytosis-induced, 327
expression of, 387–389, 391
factors inducing, 121–123
heat shock factor and, 128
in immune response, 322–328
in liver ischemia, 120–123
and MHC, 324–325
in normal cells, 126
in oxidative injury protection, 321–322
during phagocytosis, 327–328
production of, 125–128
in protein assembly, 321
protooncogenes and, 123–124
specific functions of, 320–321
synthesis, 126–130
in thermotolerance, 321–322
Heat shock response. *See also* Stress response
cellular metabolic changes in, 126–128
cytoskeletal organization in, 128
HSF in, 122, 128
hsps production in, 125–128
Hsr-omega transcription in, 134–135
protein synthesis in, 125–128
rRNA processing in, 128
specific mRNA translation in, 129–133
thermoprotection in, 125–126
Hippocampus
age-induced damage to, 357
age-related changes in, 365–366
corticosteroids and, 359
MRs/GRs in, 357, 360
in spatial memory, 463
stress effects on, 357–359
HIV infection
apoptosis in, 228
injured/dying cells role in, 227
HLA. *See* Human leukemia antigens
Homeostasis
and aging, 357
Ca^{2+} in, 98
cellular defense mechanisms network and, 5
MR-GR balance and, 357, 361–363
Hormones
in neuroendocrine aging, 337–338
in neuroendocrine-immune interactions, 338–342, 344–345
and NK cell function, 344
and thymic function restoration, 341
hprt mutations
in human populations, 26–27, 38–40
in T lymphocytes, 37
HSF. *See* Heat shock factor
Hsp. *See* Heat shock protein
Hsr-omega gene
in cell metabolism modulation, 137
expression of, 135–136
in nucleocytoplasmic regulation, 134–137
Human leukemia antigens (HLA)
and aging, 499–500
and autoimmune diseases, 499
Hutchinson-Gilford progeria, 22
Hypercorticism, 357
Hyperthyroidism, 339, 341
Hypothalamic-pituitary-adrenal (HPA) axis
adrenalectomy effect on, 358
in aging, 357, 364–369
hippocampus regulation of, 357–359
POMC processing in, 358
stress and, 358, 368–369

IFN. *See* Interferon
IGF-1
and leukemic cell lines, 155
receptor, 154–156
Immune system
in homeostasis, 396
hsps in, 322–328
neuroendocrine links with, 331

opioid peptides in, 396
stress neuropeptides in, 494–495
Immunocytes
chemotaxis of, 398
opioid peptide modulation of, 398–399
Immunological aging
in NK cell cytotoxicity, 336–337
in T-cell function, 336
thymic endocrine activity during, 336–337
thymic involution in, 336–337, 341, 397
Immunoneuroendocrine system, 331–333
Inflammation, 322
Interferon (IFN). *See also* Cytokines; Interleukins
Interferon-γ (IFN-γ)
age-related production of, 492
NK cell production of, 397
Interleukins (IL). *See also* Cytokines; Interferon
age-related decline of, 397
age-related production of, 490–492
and apoptosis, 184, 272
in neuroendocrine-immune interactions, 340, 344
and NK activity, 337, 342, 344
in stem cell proliferation, 181
in T-cell proliferation, 490
TPA+PHA-induced production of, 491
Ionizing radiation, as genotoxic agent, 4
Ischemia. *See also* Liver injury; Postischemic response
hsp synthesis in, 120–123
protein synthesis decrease in, 120
reperfusion, 322
temporary liver ischemia, 120–124

Kinases. *See also* Protein kinase C
activation of, 98
in apoptosis, 273
in endonuclease regulation, 273
in protein phosphorylation, 98–99
in signal transduction cascade, 273

Leukemia
acute, 202–203
DS susceptibility to, 11
Leukemic blast cells
cell cycle characteristics of, 202–205
differentiation arrest of, 202–204, 206–210
growth arrest of, 205–206
posttranslational abnormalities in, 206
proliferation in, 202–203
quiescence in, 203–204
rRNA processing in, 205–206
survival characteristics of, 210–211
Life span, 78, 384. *See also* Aging; Maximum life-span potential
antioxidants and, 414, 417
calorie-restricted diet and, 91, 373–374
catalase activity and, 78
and cell senescence, 250
and cellular defense network, 414–415
DNA repair and, 3, 17–18, 413–414, 417
metabolic rate and, 74–76, 385–386, 447
polygenic control of, 414–415
proliferative capacity and, 250
restricted diet and, 403, 409
and SOD activity, 78
stress proteins and, 414, 417
vs. life expectancy, 372
Lipid peroxidation
free radical tissue damage and, 444
and mitochondrial membrane integrity, 446
and oxidative cell injury, 444–446
Liver injury pathogenesis, 444, 446
reperfusion stress and, 120–124
Lymphokines. *See* Cytokines

Maillard reaction, 63–64, 69
product accumulation, 421–422
Major histocompatibility complex (MHC)
in AD, 352
in aging, 499
in apoptosis, 306, 308
and hsps, 324–325
and thymocyte maturation, 305–307
Maximum life-span potential (MLSP) of the species
antioxidant defenses and, 78–79, 82
dietary restriction and, 403, 409
energy production and, 74
increase in, 92
oxidant generation rate and, 81–82
Metabolic rate. *See also* Cell metabolism
and aging, 85–86, 406
dietary restriction and, 405–407
and DNA damage, 92
and life span, 385–386, 447
Metallothioneins, 319. *See also* Stress proteins
MFO systems. *See* Mixed-function oxidation systems
Microglia
in cell-mediated AD damage, 352–353
MHC expression by, 352
Micronuclei (MN), 7–8
age-related frequency of, 9
frequency in DS of, 11–12
and genomic instability, 7
MID. *See* Multiinfarct dementia
Mineralocorticoid receptors (MR)

distribution of, 361
in hippocampus damage, 359–360
in homeostatic control, 357
in senescence, 368
in stress response, 361–363
Mitochondria
age-related DNA defect accumulation in, 450
age-related DNA heterogeneity of, 450–451
Ca^{2+} release from, 262–266
as free radical source, 111
oxidative stress metabolism, 453–455
Mitogenesis
activation of, 487–488
and aged cells, 397
calorie restriction and, 91
and DNA damage, 88
in mutagenesis, 88–90
oxidants and, 88–90
risk factors for, 92
Mixed-function oxidation (MFO) systems, 53–54
MN. *See* Micronuclei
Molecular chaperones. *See* Chaperones
Morbidity, compression/decompression of, 372
MR. *See* Mineralocorticoid receptors
Multiinfarct dementia (MID), 351. *See also* Alzheimer's disease; Dementia
Mutagenesis, 88–89
Mutagens
and aging, 85–92
genotoxic agents as, 90
Mutations. *See also* DNA damage
age-related accumulation of, 36–40
age-related frequency of, 26–27
of *hprt* gene, 26–27, 37, 429
in human lymphocytes, 27, 36–40
of *lac*Z gene, 28–33
MyD. See Growth-arrest genes

Natural killer (NK) cells
age-related changes in, 336–337, 341–342
in centenarians, 505–506
cytokines and, 344
IFN-α production by, 397
Necrosis. *See also* Apoptosis; Cell death; Programmed cell death
apoptosis distinguished from, 231
bleb formation in, 229–230
indicators of, 218
physical agents and, 220
programmed death distinguished from, 235
Neonatal progeroid syndrome, 423. *See also* Down's syndrome; Werner's syndrome
clinical findings in, 424–425
genomic instability in, 423–425
Neoplasia, injured cells in, 227
Nerve growth factor (NGF), and DNA repair, 19
Neuroendocrine-immune interactions, 345
and age-associated diseases, 342
during aging, 339–342
biomarkers of aging in, 335–345
hormones in, 338–339
levels of, 339
major pathways of, 340
neuropeptides in, 336, 338–340
and theories of aging, 342–345
Neuroendocrine system
age-related circadian rhythmic changes in, 338
age-related hormonal changes in, 337–338
immune system interaction with, 338–345
Neurofibrillary tangles, in Down's syndrome, 11
Neuropathy, 63
myelin glycation and, 66–67
NGF. *See* Nerve growth factor
NK. *See* Natural killer cells
NMDA receptor
age-related decline in, 284
glucocorticoid activation of, 285

OFR. *See* Oxygen free radicals
Oncogenes, 196–197. *See also* Protooncogenes
and DDI, 148
in differentiation inhibition, 181
Oncogenesis. *See* Carcinogenesis
Opioid peptides
age-related levels of, 399–400
chemotactic role of, 398
distribution of, 398–399
Oxidants, 158
in aging, 85–92
and cancer, 86–87
and carcinogenesis, 158–164
and cell damage, 86
cell growth promotion by, 161–162, 164
in DNA breakage, 71–72
growth inhibition by, 160–161
and mitogenesis, 88–90
protooncogene induction by, 161–164
Oxidative injury, 319
and cytoskeletal alteration, 322
diseases associated with, 322
L-histidine and, 456–457

hsp protection against, 319–328
mechanism of, 444–446
Oxidative stress
and aging, 76–82
amino acids and, 71–72
(bi)sulfite metabolism and, 460–462
and bleb formation, 97–98
cell defense mechanisms against, 71–73
cellular targets of, 97
and cytoskeletal alterations, 97–107
cytotoxic response to, 71–73
and DNA damage, 71–72
as genotoxic agent, 4
kinase activation during, 98
mitochondrial metabolism inactivation by, 456–457
protein modification in, 100
Oxygen free radicals (OFR)
and aging, 251–255, 257–259
and cell cycle, 258
cell damage induced by, 252–255, 258
and cell proliferation, 252
and cellular morphology alterations, 253, 256, 258
and DNA damage, 253–255, 258
targets of, 252

P53, 188
in apoptosis promotion, 184
PADPRP. *See* Poly(ADP-ribose)polymerase
PHA. *See* Phytohemagglutinin
Phagocytosis
evolutionary preservation of, 332–333
POMC modulation of, 333
Phorbol esters
in apoptosis blockage, 307
and DNA fragmentation, 272–274
Phosphorylation
in AD, 98
in cytoskeletal alterations, 98–99
and degenerative disorders, 98
in energy metabolism regulation, 51
protein modification by, 49–51, 98, 163–164
Phytohemagglutinin (PHA)
and BE stimulation, 312–317
and cell proliferative capability, 252
T-cell mitogenesis activation by, 487–488
PKC. *See* Protein kinase C
Poly(ADP-ribose)polymerase (PADPRP), 253–255
and aging, 215
in antioxidant system, 252–255, 258
and apoptosis, 215
autoantibodies to, 508–509
in cell defense mechanisms, 5, 215–216
in CNS, 432–435
DNA-damage response of, 216
in DNA repair, 432–435, 508
inhibitors of, 254–255
and life span, 3
POMC. *See* Proopiomelanocortin
Postischemic response
hsp levels in, 122–123
protooncogenes in, 123–124
to temporary liver ischemia, 120–124
Potocytosis, 227, 229–231
Presbyacusis, in Down's syndrome, 11
print/screenEnergy metabolism. *See also* Calorie-restricted diet; Metabolic rate
Progeroid syndromes, 11–14, 22. *See also* Neonatal progeroid syndrome; Werner's syndrome
DS similarity to, 11–12
modified proteins in, 55
Programmed cell death. *See also* Apoptosis; Cell death; Necrosis and aging, 246–247
apoptosis distinguished from, 234–235
biological agents and, 220–225, 227. *See also* Cytokines; Interleukins; Toxins
Ca^{2+} concentration in, 273
and cell senescence, 250–251
chemical agents and, 220–227
DNA fragmentation in, 240–242
endonucleases and, 240–242, 246
gene involvement in, 227–228, 234
genetic analysis of, 243–246
heat shock and, 220
hsps in, 237–238, 245
morphological changes in, 220–231
necrosis distinguished from, 235
of neonatal retinal ganglion cells, 466–469
nuclear morphological change in, 218
pathways of, 218
physical agents and, 220, 227
physiology of, 239–240
protein synthesis in, 236–239, 242–245
RA and, 242
stages in, 230–231
structural modification and, 218, 220–227. *See also* Cell injury and tumor growth, 250–251
Progressive systemic sclerosis (PSS), 508
Proopiomelanocortin (POMC)
gene expression, 501–503
peptides derived from, 331–333
Prooxidant-induced Ca^{2+} release
from mitochondria, 262–266
specific versus nonspecific pathways, 264–266
Prooxidants. *See also* Oxidants; Reduced oxygen species

and aging, 74
and MLSP, 78–82
Protein carbonyl, 111
in AD, 115
age-related accumulation of, 112
Protein degradation
age-related changes in, 45
aging and, 44–45
ATP-dependent, 43–45
ubiquitin in, 43–44, 56
Protein elongation factors (EFs), 50–53, 55
Protein initiation factors (eIFs), 50, 55–56
Protein kinase C (PKC), 161, 164
in AD, 288
age-related decline in activity of, 284
age-related impairment of, 488
in apoptosis, 276, 307
and endonuclease, 272
in phosphorylation, 98
and signal transduction, 272
TPA activation of, 142, 148
Protein modification
ADP-ribosylation, 52–53
and aging, 43–45, 48–57
deamidation, 55
DNA synthesis and, 49–50
energy metabolism and, 51
glycation, 54–55
isomerization, 55
methylation, 51–52
MFOs in, 53–54
by OFRs, 110–116
oxidation, 53–54
phosphorylation, 49–51, 98, 163–164
posttranslational, 43–45, 48–57, 163–164
in progeria, 55
racemization, 55
and signal transduction, 50–51
in Werner's syndrome, 55
Protein oxidation
in aging brain, 110–116
biomarkers of damage in, 436–437
cell damage from, 87
Proteins
age-related functional changes in, 48
and cell death genes, 245–246
life span of, 43–45
nuclear matrix, 103, 106
OFR modification of, 110–116
oxidative damage to, 53–54, 87, 110–116
posttranslational modifications of, 43–45, 48–57, 163–164
ribosomal, 205–206
senescent-specific changes in, 189–190
Protein synthesis
aging and, 48–49, 174, 176
components of, 50
EFs and, 50–53, 55
eIFs and, 50, 53–56
heat shock and, 126–128
of hsps, 120–121
in liver ischemia, 120
in programmed cell death, 236–239, 242–245
temperature-dependent, 129–131, 133
Protooncogenes, 188–189, 196–200
and AP1 complex formation, 458
and differentiation, 181, 458
in hsp activation, 123–124
induction of, 161–164
in leukemic blast cell cycle, 202–203, 208
in leukemic cell lines, 154–155
and proliferation, 458
in quiescent growth states, 196–201
repression of, 197, 199–201
in senescent cells, 196–201
stress stability of, 149
T-antigen induction of, 197–198
in T-antigen-stimulated DNA synthesis, 198–199

Quiescence
growth-related gene expression in, 196–201
in leukemic blast cells, 203–204
protooncogenes in, 195
tumor suppressor genes in, 195–196

RA. *See* Retinoic acid
Rate-of-living theory, 75. *See also* Life span; Maximum life-span potential
Reduced oxygen species (ROS)
and age-related oxidative stress levels, 79–82
and aging, 75–76
Retinal ganglion cell neuronotrophic factor (RGNTF), 466–469
Retinoic acid
and programmed cell death, 242
in terminal differentiation, 207–208
transduction path activation by, 182
Retrovirus immunosuppression, 301–302
Rheumatoid arthritis (RA), 323, 508
RNA synthesis
in liver ischemia, 120
postischemic, 120
in terminal differentiation, 176
mRNA
age-related expression of, 463–464
and *gadd*, 149
heat shock induction of, 131
in heat shock response, 128–131, 133
preferential translation of, 129–133
in senescence, 188–189, 192

rRNA
in cell stress, 128
processing of, 205–206
ROS. *See* Reduced oxygen species

Sarcoidosis (SARC), 508
SCE. *See* Sister chromatid exchange
Scleroderma, 6
SEB. *See* Staphylococcal enterotoxin B
Selection
of immature thymocytes, 307–308
mechanisms of, 306–307
in thymus cell death, 306–308
Senescence. *See also* Aging; Apoptosis
as component of development, 295
DNA synthesis with, 187, 189, 191
genes promoting, 250
and genotoxic stress, 150
glucocorticoids in, 368
growth arrest with, 187, 199–201
growth-related gene expression in, 195–201
integrated function loss with, 190–192
and longevity, 250
molecular changes with, 187–192
mRNA levels with, 188–189
protooncogene repression in, 189, 197, 199–201
specific mRNA levels with, 188–189, 192
specific protein level changes with, 189–190
SV-40 T antigen in, 197, 200–201
T-kininogen expression in, 479
as tumor-escape strategy, 5
and tumor growth, 250–251
SGP-2. *See* Sulfated glycoprotein 2
Signal transduction
kinases in, 273
PKC and, 272
in T-cell development, 270
Sister chromatid exchange (SCE)
as DNA repair indicator, 438
frequency of, 7, 9–10
and genomic instability, 6, 14
in Werner's syndome, 429–430
Sjögren's syndrome (SS), 508
SOD. *See* Superoxide dismutase
Somatic mutation theory of aging, 85
Spatial memory
in dementia, 463–464
hippocampus role in, 463
Staphylococcal enterotoxin B (SEB), 308
and DNA fragmentation, 482
and T-cell proliferation, 481
Stress effects. *See also* Cell stress
and aging, 368–369
cystine transport induction, 497–498
on HPA axis, 358–359, 368
Stress neuropeptides, 494–495
Stress proteins. *See also* Heat shock proteins
in cellular defense mechanisms network, 5
enzymes, 319, 321
erythrophagocytosis-induced synthesis of, 327
and life span, 414, 417
metallothioneins, 319
in MHC, 319
in reperfused liver, 120–124
SOD, 321
ubiquitin, 319
Stress responses, 139–140, 322
evolutionary preservation of, 332–333
glucocorticoids in, 361–363
Stroke, 322
Sulfated glycoprotein 2 (SGP-2)
in aging, 473
apoptosis and, 471–472
in lymphoid tissues, 472–473
Sulfhydryl groups, oxidative susceptibility of, 103, 106
Sulfite metabolism
age-dependent rate differences, 462
and oxidative stress, 460
Superoxide dismutase (SOD)
in antioxidant defenses, 158–159, 164
dietary restriction and, 387–389, 391
and DNA breakage, 161
heat induction of, 321
and life span, 78–79
transfectant cells with, 159–161
Systemic lupus erythematosus (SLE), 508
hsp antibodies in, 323

T-cell maturation
apoptosis and, 305–309
MHC and, 305–307
negative selection in, 305–308
positive selection in, 305–307
thymic epithelial cells in, 308
T-cell receptor (TCR)
in apoptosis, 306
in negative selection, 306
and SEB-activated cells, 481–482
and thymocyte development, 305
T cells. *See also* Thymocytes; T lymphocytes
age-related function decline of, 336–337, 341–342
age-related mitogenic response of, 487–488
age-related PKC translocation in, 488
age-related responsiveness of, 397
mitogenesis in, 487–488
SEB-induced proliferation of, 481

T-cell selection. *See* T-cell maturation
TCR. *See* T-cell receptor
Temperature
  and hsp synthesis, 129–130
  and ribosome number, 131, 133
Terminal differentiation
  and aging, 168–177
  and apoptosis, 168, 174, 176–177, 184–185
  in fibroblast stem cell systems, 167–177
  genetic program in, 207–208
  in leukemic blast cells, 202–204, 206
  and protein synthesis, 174, 176
  retinoids in, 207
  and RNA synthesis, 176
  and transformation, 169, 171–177
Thermoprotection, 125–126
Thermotolerance, 125
  protective effect of, 127–128
Thiol oxidation
  in cytoskeletal alterations, 101–105
  prevention of, 106
Thymic involution, 397
Thymocytes. *See also* T cells; T lymphocytes
  apoptosis in, 269–273, 305–306
  HMC interaction with, 305–307
  maturation of, 269–273
  negative selection of, 305–308
  positive selection of, 305–307
  TCR genes and, 305
Thymus
  age-related involution of, 336–337, 341
  apoptosis-related changes in, 294
  hyperthyroidism and, 341
  in neuroendocrine-immune interactions, 339
  regrowth of, 339, 341
T-kininogen levels
  age-related changes in, 479–480
  diet restriction and, 479
T lymphocytes. *See also* T cells; Thymocytes
  age-impaired proliferation of, 490
  age-related mutations in, 36–40
  apoptosis of, 481–482
  hprt mutations in, 37
  negative selection and, 305–308
  positive selection and, 305–306
  proliferation of, 505–506
TNF. *See* Tumor necrosis factor
Toxins
  C. difficile A/B, 220, 223
  and cell death, 220, 223–225
  cytoskeletal, 97
  SEB, 308, 481–482
Transduction, in differentiation, 182
Transfectants
  antioxidant enzymes in, 159–161
  DNA breakage sensitivity of, 161
  growth properties of, 160–161
  inducibility of, 161
Transformation, 168
  aging and, 171–172, 174–177
  apoptosis protection against, 471
  and gene expression, 149
  terminal differentiation and, 169, 171–177
Tumor growth, cell senescence and, 250–251
Tumor necrosis factor-α (TNF-α)
  age-related production of, 491–492
  and blebbing, 220–222, 227
Tumor-suppressor genes, 196–201

Ubiquitin, 43–44
  in aging, 56
UDS. *See* Unscheduled DNA synthesis
Undifferentiated connective tissue disease (UCTD), 508
Unscheduled DNA synthesis, 3, 17
UV irradiation
  and CS cells, 418–420
  and DNA damage, 4, 17, 23
  as genotoxic agent, 4

Werner's syndrome (Ws). *See also* Down's syndrome; Neonatal progeroid syndrome
  genomic instability in, 429
  genotoxic agent sensitivity in, 429–431
  immunological alterations in, 429–431
  lymphocyte populations in, 430
  modified proteins in, 55
  somatic mutation rate in, 22

Zeiosis, 227, 229–230
Zinc
  age-related turnover of, 344–345
  in lymphocyte proliferation, 342
  in neuroendocrine-immune interactions, 344
  and PKC activity increase, 272
  in thymic "rejuvenation," 339, 341, 345
Zn^{2+}
  in DNA damage blockage, 216
  and DS, 216